Abstract:Abstract Background Both the American Gastroenterological Association (AGA) and the European Crohn's and Colitis Organisation (ECCO) recommend to continue biologic during the whole pregnancy and until the third trimester, respectively. However, these positions are associated with a baby's exposure to the drug and from our clinical practice are not necessarily in line with patients' wishes and fears. In patients in full clinical and biologic remission, stopping biologic before it is actively transported through the placenta (around the week 20) would be a possible approach to get around these drawbacks. We aimed to assess the outcome of disease activity and pregnancies in patients stopping biologic before the week 20. Methods We performed a retrospective monocentric study. All patients who gave birth between 2010 and 2023 were included. The following parameters were collected: clinical and demographic characteristics, biomarkers (CRP and faecal calprotectin before pregnancy and during the 3 trimesters), IBD treatment at time of pregnancy, whether it was stopped during pregnancy, when and in what circumstance (patient versus medical agreement). We also looked at the disease course, whether a relapse occurred (defined as the need to take corticosteroids, a biologic, or surgical resection), and the pregnancy outcome. Results A total of 185 pregnancies were reported in 143 patients (73.4% Crohn disease and 26.6% ulcerative colitis). Patient's characteristics are shown in Table 1. Among these women, 106 (74.1%), 32 (22.4%) and 5 (3.5%) reported one, two or 3 or more pregnancies, respectively. Figure 1 summarises the treatments during these reported pregnancies, disease activity outcomes and pregnancy outcomes. The biologic was stopped before conception for 9 pregnancies and 90 pregnancies started under biologics (anti-TNF, vedolizumab or ustekinumab). Of these, biologic was continued until delivery in 10 (11.1%) patients, whereas it was stopped before the week 20 for the others (88.9%). Among patients who stopped biologics before conception, before the week 20, and those who continued biologics through delivery: 3/9 (33.3%), 13/80 (16.3%; including 10/66 or 15.2% among those stopping on medical agreement) and 4/10 (40%) relapsed, respectively. Among the 10 relapses in patients who stopped in first trimester on medical agreement, 6 had normal biomarkers before cessation (unknown for the others). Conclusion Biologic discontinuation before week 20 on medical agreement was associated with relapse in 15.2% of cases. Fate of disease activity and pregnancies in patients stopping biologic before week 20 should be studied prospectively in a dedicated study.

A Case of Ulcerative Colitis During Pregnancy and Childbirth at an Older Age While on Biologic Therapy

S3976 A Case of an Uncomplicated Pregnancy on Dual Biologic Therapy With Ustekinumab and Vedolizumab for Crohn's Disease

Biological Therapy of Traditional Therapy-Resistant Adult-Onset Still’s Disease: an Evidence-Based Review

Case report: A pregnant woman with Crohn disease who used ustekinumab to the 3rd trimester developed severe infection

A Survey of Pregnancy Outcomes for Women of Childbearing Age with Inflammatory Bowel Disease in South China

P1075 Outcomes in patients stopping biologic during the first trimester of pregnancy : a retrospective monocentric study

A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy

Inflammatory bowel disease in pregnancy and breastfeeding

Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity

Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan

Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis

Pregnancy outcomes among women with inflammatory bowel disease: A UK tertiary centre experience

Effect of Anti-TNF Biologic Exposure During Pregnancy on Villitis of Unknown Etiology Diagnoses in Patients with Autoimmune Disease

Safety of biologic agents for the management of rheumatic diseases during pregnancy

P017 Planned infliximab use during pregnancy for pakistani patients with immune-mediated inflammatory disease - case series of 12 patients

S1074 Impact of Inflammatory Bowel Disease on the Outcomes of Pregnancy: A National Inpatient Sample Analysis

[Inflammatory bowel disease during pregnancy and childbirth]

Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease

Relapse of colchicine-intolerant, corticosteroid-dependent recurrent idiopathic pericarditis after perigestational discontinuation of anakinra: uncertain safety of anakinra in pregnancy and the need for shared decision-making

Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000

A Benefit–Risk Conceptual Framework for Biologic Use During Pregnancy: A Mini‐Review